ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Crossbow Therapeutics has landed $80 million in series A funding led by Pfizer Ventures and MPM BioImpact for the development of cancer immunotherapies. The company’s pipeline consists of antibodies that mimic T-cell receptors and can recognize peptides bound to the major histocompatibility complex molecules on the surfaces of cancer cells. After binding, the antibodies rouse the immune system to attack the targeted tumors cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X